Last reviewed 2026-04-23 · How we verify

cisplatin i.p.

Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.

Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells. Used for Ovarian cancer (intraperitoneal administration), Colorectal cancer (intraperitoneal administration), Gastric cancer (intraperitoneal administration).

At a glance

Mechanism of action

Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block replication and transcription machinery. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific and has been a cornerstone of cancer chemotherapy for decades.

Approved indications

• Ovarian cancer (intraperitoneal administration)
• Colorectal cancer (intraperitoneal administration)
• Gastric cancer (intraperitoneal administration)

Common side effects

• Nephrotoxicity
• Ototoxicity
• Nausea and vomiting
• Myelosuppression
• Peripheral neuropathy
• Electrolyte abnormalities (hypomagnesemia, hypokalemia)

Key clinical trials

• Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer (PHASE3)
• Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer (PHASE1)
• Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.